Matches in Wikidata for { <http://www.wikidata.org/entity/Q64675804> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q64675804 description "assaig clínic" @default.
- Q64675804 description "clinical trial" @default.
- Q64675804 description "clinical trial" @default.
- Q64675804 description "clinical trial" @default.
- Q64675804 description "clinical trial" @default.
- Q64675804 description "ensaio clínico" @default.
- Q64675804 description "ensayo clínico" @default.
- Q64675804 description "ensayu clínicu" @default.
- Q64675804 description "essai clinique" @default.
- Q64675804 description "klinisch onderzoek" @default.
- Q64675804 description "клінічне випробування" @default.
- Q64675804 name "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)" @default.
- Q64675804 type Item @default.
- Q64675804 label "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)" @default.
- Q64675804 prefLabel "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)" @default.
- Q64675804 P1050 Q64675804-E13155AD-4109-4057-A530-4E346940E476 @default.
- Q64675804 P1132 Q64675804-35E922FC-9D06-4189-BF99-CB5D13AB1C27 @default.
- Q64675804 P1476 Q64675804-090203B5-0AAA-48C1-924D-56ABCCADEFAC @default.
- Q64675804 P17 Q64675804-FD1FBC9F-F840-4FD7-8382-4E3FDE6AA9C8 @default.
- Q64675804 P1813 Q64675804-844EA31A-2504-4583-A7A7-6626D2271E0C @default.
- Q64675804 P2899 Q64675804-014CAE4B-EFCF-4903-9111-875B1BDC485F @default.
- Q64675804 P3098 Q64675804-975356FF-6579-46E1-84BB-FC1BE80ED7AA @default.
- Q64675804 P31 Q64675804-F798FB5C-ADAE-488D-989C-E31042604DFA @default.
- Q64675804 P4844 Q64675804-2AD7BEA5-F413-4E5B-BAD9-8C6884310F42 @default.
- Q64675804 P580 Q64675804-D8B260F9-3750-4DDD-8E5E-85052337387C @default.
- Q64675804 P582 Q64675804-61B0DC61-AAE0-41DB-80C0-99992016FF59 @default.
- Q64675804 P6099 Q64675804-ECEB9171-BAE0-4955-9394-51BBBE90C83B @default.
- Q64675804 P6153 Q64675804-E46EFEAA-2F12-4966-AAE5-5E808309E39B @default.
- Q64675804 P8363 Q64675804-A417B2A8-F048-45CA-89C3-0EBDA4E5F527 @default.
- Q64675804 P1050 Q12206 @default.
- Q64675804 P1132 "+69" @default.
- Q64675804 P1476 "A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes" @default.
- Q64675804 P17 Q17 @default.
- Q64675804 P1813 "GETGOAL-MONO" @default.
- Q64675804 P2899 "+20" @default.
- Q64675804 P3098 "NCT00905255" @default.
- Q64675804 P31 Q30612 @default.
- Q64675804 P4844 Q6659956 @default.
- Q64675804 P580 "2009-05-01T00:00:00Z" @default.
- Q64675804 P582 "2011-01-01T00:00:00Z" @default.
- Q64675804 P6099 Q42824827 @default.
- Q64675804 P6153 Q158205 @default.
- Q64675804 P8363 Q78089383 @default.